Medical New Treatment for TBI using a C1q Blocker

  • Thread starter Thread starter berkeman
  • Start date Start date
  • Tags Tags
    Treatment
AI Thread Summary
A recent study from San Francisco researchers highlights a promising new treatment for traumatic brain injuries (TBI), which could significantly improve outcomes if administered shortly after the injury occurs. The research identifies an increase in the molecule C1q in the thalamus following TBI, which is linked to chronic neuronal loss, inflammation, sleep disruption, and the onset of epileptic spikes. By blocking C1q with an antibody developed by Annexon Biosciences, the study demonstrated the potential to prevent these debilitating symptoms. Current therapies for TBI are limited, particularly those that can halt neurodegeneration. The antibody treatment shows promise, with clinical trials already underway for other conditions, suggesting a future application for TBI if results remain positive. With approximately 69 million people affected by TBI globally each year, this breakthrough could represent a significant advancement in treatment options.
berkeman
Admin
Messages
69,173
Reaction score
24,243
Interesting article about a new treatment for Traumatic Brain Injury, which looks to be pretty effective if given soon after the injury:

SF researchers find possible breakthrough in treating traumatic brain injuries​


SAN FRANCISCO (KGO) -- From battlefield explosions, to violent sports injuries, millions of patients suffer the lifetime effects of traumatic brain injuries. Treating the symptoms is often a frustrating challenge.

Now, there's hope for a possible breakthrough.

"What we found is that after the traumatic brain injuries, there is an up-regulation in this molecule called C1q, and especially in a deep brain area called the Thalamus. And when we blocked this molecule we were able to prevent the chronic neuronal loss, and the chronic inflammation and the sleep disruption and the development of epileptic spikes," Paz explains.

In other words, major symptoms of TBI.

The blocker they used was an antibody, being developed by South San Francisco-based Annexon Biosciences. Ted Yednock, Ph.D., is chief innovation officer.

"In traumatic brain injury, there aren't really any available therapies, especially any that prevent the neurodegenerative process from happening. So what's really interesting about Dr. Paz's study, is that even 24 hours after the injury, she found that she could treat, use our treatment to block this process," says Yednock.The company is already conducting clinical trials of the inhibitor for treating ALS and other conditions and could potentially expand to TBI in the future if the results are encouraging. And with causes ranging from car crashes to simple falls, some 69 million people around the world are believed to suffer from traumatic brain injury every year.

https://abc7news.com/gladstone-institute-san-francisco-traumatic-brain-injury-tbi/11217278/
 
Biology news on Phys.org
I've been reading a bunch of articles in this month's Scientific American on Alzheimer's and ran across this article in a web feed that I subscribe to. The SA articles that I've read so far have touched on issues with the blood-brain barrier but this appears to be a novel approach to the problem - fix the exit ramp and the brain clears out the plaques. https://www.sciencealert.com/new-alzheimers-treatment-clears-plaques-from-brains-of-mice-within-hours The original paper: Rapid amyloid-β...
https://www.discovermagazine.com/the-deadliest-spider-in-the-world-ends-lives-in-hours-but-its-venom-may-inspire-medical-miracles-48107 https://en.wikipedia.org/wiki/Versutoxin#Mechanism_behind_Neurotoxic_Properties https://www.sciencedirect.com/science/article/abs/pii/S0028390817301557 (subscription or purchase requred) The structure of versutoxin (δ-atracotoxin-Hv1) provides insights into the binding of site 3 neurotoxins to the voltage-gated sodium channel...
Back
Top